Recombinant Human Serum Albumin Market

Updated On : 03 June 2025

RECOMBINANT HUMAN SERUM ALBUMIN MARKET OVERVIEW

The global recombinant human serum albumin market size was USD 83.3 million in 2025 and is projected to touch USD 128 million by 2033, exhibiting a CAGR of 7.4% during the forecast period.

Recombinant human serum albumin, rHSA, is another artificially synthesized variety of albumin that is normally found in human blood plasma. By translating the coding sequence of the human serum albumin gene into expression systems for bulk-protein synthesis, such as yeast or mammalian cells, rHSA protein is derived. rHSA is used usually as a supplement to a cell culture medium in biopharmaceutical manufacture and as a stabilizing agent in many formulation types used for therapeutic purpose in view of important functions concerning osmotic pressure maintenance and inhibition of protein degradation.

The different applications of rHSA include mostly topical practices in biotechnology industries and pharmacological work as well as some research and practical field applications involving protein analysis and enzyme-linked immunosorbent assays (ELISA). Being produced in a controlled environment, it is, therefore, a much safer and more ethical alternative than serum albumin derived from human blood, which is subject to the risks of pathogen contamination and spread of diseases. As a result of this artificial protein, personalized medicine might give much extra efficiency to the development process for very slow-moving products like vaccines and drugs.

GLOBAL CRISES IMPACTING NEUROGENETIC TESTING MARKETCOVID-19 IMPACT

"Recombinant Human Serum Albumin Industry Had a Positive Effect Due to Increased Demand for rHSA during COVID-19 Pandemic"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The demand for recombinant human serum albumin has seen an enormous increase due to its role in the development of vaccines, gene therapy, cell therapy, and other biopharmaceutical products. It finds use as a stabilizing agent and an excipient in various formulations, thus requiring paramount importance to assure stability and efficacy of biopharmaceutical products. For instance, rHSA is used in a marketed product called Exbumin, a recombinant human serum albumin manufactured by InVitria for the stabilization of vaccines and cell and gene therapies, thereby further adding to the dependency on rHSA during the pandemic.

The pandemic-related surge in demand disrupted the supply chain of rHSA. Disruption was reported with respect to delay of the procurement of raw materials, challenges in manufacturing operations, and disturbances in distribution processes. Therefore, all of these challenges hindered the availability of rHSA for urgent applications and highlighted the importance of a more resilient biopharmaceutical supply chain.

LATEST TREND

"Shift Toward Plant-Derived Production to Drive Market Growth"

There have been notable developments in the market which has the potential to boost the recombinant human serum albumin market share. the companies that are behind this type of production to create rHSA free from animal, virus, and bacterial contaminations have tried to alleviate certain ethical concerns in favor of the product's safer quality. This innovation follows an emerging trend towards cheap yet sustainable production systems for biopharmaceuticals where plant systems can provide an alternative that is more scale-independent and environmentally friendlier than conventional mammalian cell cultures.

RECOMBINANT HUMAN SERUM ALBUMIN MARKET SEGMENTATION

BY TYPE

Based on Type, the global market can be categorized into OsrHSA and ScrHSA.

• OsrHSA: osrHSA is a recombinant variant formed from human serum albumin produced in sheep cells. It acts as a replacement for albumin derived from human sources, in particular for its use in several biopharmaceutical applications, such as vaccine production and in culture media for cells.

• ScrHSA: scrHSA is a recombinant form of human serum albumin manufactured in swine cells, and it is structured and designed to mimic the function of human albumin in biopharmaceutical production such as in the manufacture of therapeutics and vaccines.

BY APPLICATION

Based on application, the global market can be categorized into Cell Culture Media and Medical Supplements.

• Cell Culture Media: Animal cell culture media are defined as specialized solutions specifically designed to grow and maintain animal cells under laboratory conditions. Such media provide all essential nutrients, vitamins, minerals, and conditioners or growth factors to support cell proliferation and metabolism.

• Medical Supplement: Medical supplements are articles intended to supply essential nutrients or any substances that can otherwise be lacking or in much greater amounts for some medical reason. Such nutraceuticals include vitamins, minerals, amino acids, and proteins, and they are used mainly for recovery, improving nutritional intake, or treating a specific deficiency.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

DRIVING FACTORS

"Increasing Demand in Biopharmaceuticals to Boost the Market"

There are several elements inspiring the recombinant human serum albumin market growth. Recombinant human serum albumin is the most prominent biopharmaceutical requisition for the manufacture of vaccines, gene therapies, and monoclonal antibodies. It plays a role as a stabilizer in any formulation of biologics, ensuring stability of the drugs and preventing degradation of proteins even during storage and transport. Increasing demand for different biopharmaceuticals, especially biopharmaceutical drugs, is going to keep the need for good-quality rHSA at an all-time high-both on the research and production side.

"Growth in Cell Therapy Development to Expand the Market"

This application of recombinant human serum albumin is gaining grounds in the production of vaccines and cell-based therapies with special reference to COVID-19 vaccine development and gene and other cell-based therapies. The demand has increased for recombinant human serum albumin as an agent to stabilize cell culture media as the focus of the world on the development of vaccines and gene therapy intensifies.

RESTRAINING FACTOR

"Ethical Concerns with Animal-Derived Recombinant Products to Potentially Impede Market Growth"

While the production of rHSA takes place predominantly in non-human expression systems using yeast or mammalian cells, some production processes still rely on animal-based systems. This poses ethical problems, especially for stakeholders whose industries prioritize animal welfare. Although the shift is being made towards more ethical production processes, the view of animal-derived components in recombinant products may deter their wider acceptance. While rHSA is a common choice in biotech and the pharmaceutical field, certain areas may still utilize human-derived albumin due to its long-standing use and availability-based perspective, especially regarding small-scale research or less-regulated markets.

OPPORTUNITY

"Increasing Demand for Personalized Medicine to Create Opportunity for the Product in the Market"

There is just a future opportunity in terms of recombinant human serum albumin (rHSA) with personalized medicine. More and more personalized therapies will focus on the individual specific genetic profile, while their biologic formulations will need to have extreme specificity and stability. rHSA will be at the heart of personalized therapy development, as it is able to improve the stability and efficacy of biopharmaceuticals such as these. Certainly, this would mark a shift from gene to cell therapy and from regenerative medicine. Thus, a critical need for recombinant albumin will be invoked as part of the media and therapeutics used in cell culture.

CHALLENGE

"Managing Production Scale and Costs Could Be a Potential Challenge for Consumers"

Even the pro-recombinant technology adept developed efficiency in production. These are not yet for solving the problem of scaling up production without having to sacrifice quality or drive-up costs. Raw materials are very expensive, and costs of specialized equipment and highly controlled production environments are prohibitive. In addition, the process of production is complex, and it achieves optimum yields as well as purity; thus, rHSA manufacturers have to innovate quite constantly for improved cost effectivity.

RECOMBINANT HUMAN SERUM ALBUMIN MARKET REGIONAL INSIGHTS

• • 

• NORTH AMERICA

North America is the fastest-growing region in this market. The United States recombinant human serum albumin market has been growing exponentially owing to multiple reasons. This developmental trend of recombinant human serum albumin (rHSA) is observed in North America, particularly the United States, as most innovations in rHSA are dependent on the advancements in biotechnology and demand by the biopharmaceutical industry. This regional research foundation coupled with investments in personalized medicine and gene therapies is triggering the application of rHSA in drug development and to manufacture vaccine. Regulatory agencies such as the FDA support innovation and adoption of rHSA for clinical applications. The prompting of increased industrial production would thus be effort put into developing cost-effective scaling methods for rHSA production.

• EUROPE

The European market for recombinant human serum albumin is at a growth phase, mainly attributed to phenomenal regulatory arrangements that emphasize to states, specifically the European Medicines Agency (EMA) guidelines on the recombinant use of proteins other than animal-derived products. It is clear that countries such as Germany, UK, and France are investing heavily in biotechnology and biopharmaceutical research and hence increasing the demand for efficient and high-quality rHSA in vaccine and therapeutic developments. In an effort to be true to sustainability and ethics, European companies are inclined to the development of rHSA within the plant-based and mammalian cell expression systems because they have established a base in the education and research areas.

• ASIA

However, the recombinant human serum albumin market in Asia Pacific is growing at an upward trajectory as the region enters a new focus on biopharmaceutical manufacturing and cell-based therapies. Countries such as China, India, and Japan are investing heavily into biotechnology, to the extent of opening new horizons for the co-production of vaccines and biologics. While they are working hard to grow local manufacturing facilities and shift towards domestic production of recombinant proteins, this has not eliminated dependency on imports completely. With that notwithstanding, cost remains the main concern in the region, and therefore manufacturers strive to find possible ways to scale up production of rHSA cost-effectively for their markets.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market Through Innovation and Market Expansion"

Key industry players are shaping the recombinant human serum albumin marketplace through strategic innovation and market expansion. These companies are introducing advanced techniques and processes to improve the quality and performance of their offerings. They are also expanding their product lines to include specialized variations, catering to diverse customer preferences. Additionally, they are leveraging digital platforms to increase market reach and enhance distribution efficiency. By investing in research and development, optimizing supply chain operations, and exploring new regional markets, these players are driving growth and setting trends within the recombinant human serum albumin.

LIST OF TOP RECOMBINANT HUMAN SERUM ALBUMIN COMPANIES

• Albumedix [U.K.] 
• Merck & Co., Inc. [U.S.]
• InVitria [U.S.]
• National Compound Pharmacy Corporation [China]
• Oryzogen [France]

KEY INDUSTRY DEVELOPMENT

August 2024: InVitria took significant strives ahead in the recombinant human serum albumin marketplace. They recently developed Optibumin® 20 – Recombinant Human Serum Albumin. Thus, this formulation can be represented as 20% liquid formulation that has been tailored specifically for cell therapy processes, recombinant protein formulations, and the manufacture of biopharmaceuticals. It has high mercaptoalbumin content, thus improving drug conjugation and solubilization, and is best suited for application in drug delivery systems and vaccine stabilization.

REPORT COVERAGE

SWOT analysis is presented in this work at a high level, and helpful recommendations regarding further evolvement of the market are considered. This paper takes an opportunity to review and discuss the market segments and possible applications that have the potential to influence the market growth in the future years. The work uses both, the data regarding the modern state of the market and the information on its evolution to identify the possible development trends.

The recombinant human serum albumin with better portability is expected to gain high growth rates due to better consumer adoption trends, increasing application areas, and more innovative product developments. Yet, there might be some problems like, for instance, the shortage of raw materials or higher prices for them However, the growing popularity of specialized offerings and tendencies towards enhancing quality foster the growth of the market. All of them are progressing through technology and innovative strategies in developments as well as in supply chain and market. Due to changes in the market environment and growing demand for variety, the recombinant human serum albumin has a promising development since it constantly develops and expands its application.